52 results
8-K
EX-99.1
ZVRA
Zevra Therapeutics Inc
20 Nov 23
Zevra Therapeutics Completes Acquisition of Acer Therapeutics in its Journey to Become a Leading Rare Disease Company
7:36am
management, for the chronic management of adult and pediatric patients weighing 20 kg (44 pounds) or greater and with a body surface area (BSA) of 1.2 m2
8-K
EX-99.1
ZVRA
Zevra Therapeutics Inc
7 Nov 23
Zevra Therapeutics Reports Corporate Updates and Third Quarter 2023 Financial
7:25am
:
Narcolepsy is a chronic debilitating central disorder of hypersomnolence. The primary symptom of narcolepsy is excessive daytime sleepiness characterized
424B3
ZVRA
Zevra Therapeutics Inc
10 Oct 23
Prospectus supplement
5:07pm
and clinical safety and efficacy data from the reference listed drug (“RLD”), BUPHENYL® powder, which is approved as adjunctive therapy in the chronic … , prevention, or treatment of a life-threatening, seriously debilitating or
serious and chronic condition and when, without incentives, it is unlikely
S-4/A
ZVRA
Zevra Therapeutics Inc
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
is approved as adjunctive therapy in the chronic management of patients with UCDs involving deficiencies of CPS, OTC or AS. In Acer’s NDA, Acer also … is granted for products intended for the diagnosis, prevention, or treatment of a life-threatening, seriously debilitating or
serious and chronic condition
S-4
7nmamo
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
425
wsgemiq vdcdjjz
31 Aug 23
Business combination disclosure
8:03am
8-K
EX-99.2
jwtak5
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
8-K
EX-99.1
1z78d81ey jh794h
14 Aug 23
Zevra Therapeutics Reports Corporate Updates and Second Quarter 2023
7:48am
8-K
it3gmyuxm8t7yn8v6o2
29 Nov 22
Departure of Directors or Certain Officers
7:53am
8-K
EX-99.1
5j9x3idsqgebe1045f
16 May 22
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
8:40am
8-K
EX-99.2
e1m vezll5me9
16 May 22
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
8:40am
424B3
02zg7g2
10 Nov 21
Prospectus supplement
5:19pm
424B3
t2itd6m
16 Aug 21
Prospectus supplement
12:00am
424B3
dna3xm ca
13 May 21
Prospectus supplement
9:11pm
424B3
woqef11
11 Mar 21
Prospectus supplement
9:56pm